Predictive Biomarkers for Barrett's Esophagus: So Near and Yet So Far

Overview

Journal Dis Esophagus

Publisher Oxford University Press

Specialty Gastroenterology

Date 2013 Jan 16

PMID 23316980

Citations 12

Authors

M R Timmer

G Sun

E C Gorospe

C L Leggett

L Lutzke

K K Krishnadath

K K Wang

Affiliations

Soon will be listed here.

Abstract

Barrett's esophagus (BE) is the strongest risk factor for the development of esophageal adenocarcinoma. However, the risk of cancer progression is difficult to ascertain in individuals, as a significant number of patients with BE do not necessarily progress to esophageal adenocarcinoma. There are several issues with the current strategy of using dysplasia as a marker of disease progression. It is subject to sampling error during biopsy acquisition and interobserver variability among gastrointestinal pathologists. Ideal biomarkers with high sensitivity and specificity are needed to accurately detect high-risk BE patients for early intervention and appropriate cost-effective surveillance. To date, there are no available molecular tests in routine clinical practice despite known genetic and epigenetic aberrations in the Barrett's epithelium. In this review, we present potential biomarkers for the prediction of malignant progression in BE. These include markers of genomic instability, tumor suppressor loci abnormalities, epigenetic changes, proliferation markers, cell cycle predictors, and immunohistochemical markers. Further work in translating biomarkers for routine clinical use may eventually lead to accurate risk stratification.

Citing Articles

Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.

Uno K, Koike T, Hatta W, Saito M, Tanabe M, Masamune A Diagnostics (Basel). 2022; 12(10).

PMID: 36292126 PMC: 9600913. DOI: 10.3390/diagnostics12102437.

Multicenter Randomized Controlled Trial of Surveillance Versus Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia: The SURVENT Trial: Study Rationale, Methodology, Innovation, and Implications.

Wani S, Souza R, Durkalski V, Serrano J, Hamilton F, Shaheen N Gastroenterology. 2022; 163(3):556-562.e4.

PMID: 35679951 PMC: 9398991. DOI: 10.1053/j.gastro.2022.05.051.

Recurring Translocations in Barrett's Esophageal Adenocarcinoma.

Bajpai M, Panda A, Birudaraju K, Van Gurp J, Chak A, Das K Front Genet. 2021; 12:674741.

PMID: 34178034 PMC: 8220202. DOI: 10.3389/fgene.2021.674741.

Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.

Maitra I, Date R, Martin F Clin J Gastroenterol. 2020; 13(5):635-649.

PMID: 32495144 PMC: 7519897. DOI: 10.1007/s12328-020-01135-2.

Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett's Esophagus Compared to Esophageal Adenocarcinoma.

OFarrell N, Phelan J, Feighery R, Doyle B, Picardo S, Ravi N Int J Mol Sci. 2019; 20(18).

PMID: 31509954 PMC: 6770156. DOI: 10.3390/ijms20184449.

References

Galipeau P, Li X, Blount P, Maley C, Sanchez C, Odze R . NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4(2):e67. PMC: 1808095. DOI: 10.1371/journal.pmed.0040067. View

Lee S, Han M, Lee K, Back S, Hwang D, Kim H . Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia. PLoS One. 2012; 7(5):e37571. PMC: 3358277. DOI: 10.1371/journal.pone.0037571. View

Finley J, Reid B, Odze R, Sanchez C, Galipeau P, Li X . Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev. 2006; 15(8):1451-7. DOI: 10.1158/1055-9965.EPI-05-0837. View

Polednak A . Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003; 105(1):98-100. DOI: 10.1002/ijc.11029. View

Reid B, Levine D, Longton G, Blount P, Rabinovitch P . Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95(7):1669-76. PMC: 1783835. DOI: 10.1111/j.1572-0241.2000.02196.x. View

Reid B, Prevo L, Galipeau P, Sanchez C, Longton G, Levine D . Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001; 96(10):2839-48. PMC: 1808263. DOI: 10.1111/j.1572-0241.2001.04236.x. View

van Dekken H, Hop W, Tilanus H, Haringsma J, van der Valk H, Wink J . Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008; 130(5):745-53. DOI: 10.1309/AJCPO31THGVEUIDH. View

Chao D, Sanchez C, Galipeau P, Blount P, Paulson T, Cowan D . Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res. 2008; 14(21):6988-95. PMC: 2587072. DOI: 10.1158/1078-0432.CCR-07-5063. View

Going J, Keith W, Neilson L, Stoeber K, Stuart R, Williams G . Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut. 2002; 50(3):373-7. PMC: 1773132. DOI: 10.1136/gut.50.3.373. View

10.

Selaru F, Zou T, Xu Y, Shustova V, Yin J, Mori Y . Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002; 21(3):475-8. DOI: 10.1038/sj.onc.1205111. View

11.

Clement G, Braunschweig R, Pasquier N, Bosman F, Benhattar J . Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol. 2005; 208(1):100-7. DOI: 10.1002/path.1884. View

12.

Pepe M, Etzioni R, Feng Z, Potter J, Thompson M, Thornquist M . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-61. DOI: 10.1093/jnci/93.14.1054. View

13.

Abrams J, Kapel R, Lindberg G, Saboorian M, Genta R, Neugut A . Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009; 7(7):736-42. PMC: 3139243. DOI: 10.1016/j.cgh.2008.12.027. View

14.

Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H . ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008; 320(5876):661-4. DOI: 10.1126/science.1156906. View

15.

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y . Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005; 24(25):4138-48. DOI: 10.1038/sj.onc.1208598. View

16.

Barr Fritcher E, Brankley S, Kipp B, Voss J, Campion M, Morrison L . A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol. 2008; 39(8):1128-35. PMC: 2614867. DOI: 10.1016/j.humpath.2008.02.003. View

17.

Montgomery E, Bronner M, Goldblum J, Greenson J, Haber M, Hart J . Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001; 32(4):368-78. DOI: 10.1053/hupa.2001.23510. View

18.

Leedham S, Preston S, McDonald S, Elia G, Bhandari P, Poller D . Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut. 2008; 57(8):1041-8. PMC: 2564832. DOI: 10.1136/gut.2007.143339. View

19.

Bani-Hani K, Martin I, Hardie L, Mapstone N, Briggs J, Forman D . Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000; 92(16):1316-21. DOI: 10.1093/jnci/92.16.1316. View

20.

Sirieix P, ODonovan M, Brown J, Save V, Coleman N, Fitzgerald R . Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res. 2003; 9(7):2560-6. View